What’s certified, what’s pending, and where flights start first.

Molecular-scale assemblers are fascinating—but the commercial stack isn’t there.

A business-first tour of proven nano wins—what they do, who buys them, and why they matter.

Why “nanobots in the bloodstream by the 2030s” underestimates the commercial, clinical and regulatory grind.

What it takes to move from pilots to predictable freight.

What fixed-wing electrics must clear for regional routes to pencil out.

Keeping promises means building factories, not just physics.